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Porcine reproductive and respiratory syndrome (PRRS) is one of the most devastating and costly diseases to the swine industry
worldwide. Overall, the adaptive immune response to PRRS virus (PRRSV) is weak, which results in delayed elimination of virus
from the host and inferior vaccine protection. PRRSV has been shown to induce a meager alpha interferon (IFN-) response,
and we hypothesized that elevated IFN- levels early in infection would shorten the induction time and increase elements of the
adaptive immune response. To test this, we measured both antibody and cell-mediated immunity in pigs after the administra-
tion of a nonreplicating human adenovirus type 5 vector expressing porcine IFN- (Ad5–pIFN-) at the time of PRRSV infec-
tion and compared the results to those for pigs infected with PRRSV alone. Viremia was delayed, and there was a decrease in vi-
ral load in the sera of pigs administered the Ad5–pIFN-. Although seroconversion was slightly delayed in pigs receiving Ad5–
pIFN-, probably due to the early reduction in viral replication, little difference in the overall or neutralizing antibody response
was seen. However, there was an increase in the number of virus-specific IFN--secreting cells detected in the pigs receiving
Ad5–pIFN-, as well as an altered cytokine profile in the lung at 14 days postinfection, indicating that the presence of IFN- at
the time of infection can alter innate and adaptive immune responses to PRRSV.
Porcine reproductive and respiratory syndrome virus (PRRSV)is a widely disseminated virus of swine that causes interstitial
pneumonia and abortions and late-term fetal death in sows (7,
30). PRRSV is a member of the Arteriviridae family (positive-sense
single-stranded RNA) and primarily infects cells of the monocyte/
macrophage lineage (24). Infection with PRRSV is characterized
by prolonged viral persistence, and current vaccines fail to provide
disease control, especially against genetically unrelated strains
(38). The recent emergence of highly pathogenic strains of PRRSV
in Asia highlights the importance of finding methods to control
PRRSV disease and spread (15, 35, 36).
In general, both the innate and adaptive immune responses to
PRRSV are suppressed. Compared to other viruses that infect the
respiratory epithelial cells, such as swine influenza virus or por-
cine respiratory coronavirus, PRRSV appears to induce only mod-
est levels of alpha interferon (IFN-) and proinflammatory cyto-
kines (1, 14, 18, 25, 37). Additionally, the host response following
PRRSV infection has been characterized as both ineffective and
delayed. Although nonneutralizing antibodies are rapidly pro-
duced following infection, there is a deficiency in neutralizing an-
tibody production (40). Cell-mediated immune responses, typi-
cally measured by increases in PRRSV-specific IFN--producing
cells, can take 4 to 8 weeks to develop (4, 16, 22). Several groups
have reported increased interleukin-10 (IL-10) production in re-
sponse to PRRSV infection and suggested that this may be immu-
nosuppressive, since IL-10 has been shown to suppress antigen-
presenting cell activities, such as processing and presenting
antigen, and IL-1, IL-12, IL-18, tumor necrosis factor alpha (TNF-
), and type I IFN expression (8, 10, 26, 33, 34).
Type I interferons, such as IFN- and IFN-, have an impor-
tant role in the innate and adaptive immune response. They
contribute to innate antiviral immunity by promoting production
of antiviral mediators such as PKR (double-stranded RNA-depen-
dent protein kinase) and Mx (myxovirus resistant; IFN-inducible
GTPase) and elicit NK cell activity for the killing of virus-infected
cells (2, 3, 13, 27). IFN- and - also play a role in the adaptive
immune response by inducing both the maturation of dendritic
cells into professional antigen-presenting cells and macrophage
development and maturation and, along with IL-6, promoting B
cell differentiation into plasma cells (5, 11, 21). Several mecha-
nisms as to how PRRSV inhibits type I IFN production have been
proposed, and multiple mechanisms may apply. PRRSV has been
shown to inhibit double-stranded RNA activation of interferon
regulatory factor 3 (IRF3) via inactivation of IFN- promoter
stimulator 1 (IPS-1), an adaptor molecule in the retinoic acid-
inducible gene 1 (RIG-1) pathway (20). Others have proposed
that PRRSV interferes with modification of IB through either
nsp2 ovarian tumor domain-mediated inhibition of polyubiquiti-
nation or nsp1-mediated inhibition of phosphorylation, ulti-
mately leading to impairment of NF-B activity (31, 32).
In a previous report, we showed, using a nonreplicating ade-
novirus type 5 (Ad5) vector to deliver porcine IFN- (pINF-) to
the pig, that increased levels of IFN- at the time of challenge
delays PRRSV viremia and lessens the severity of disease (6). The
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goal of this study was to test the effect of elevated IFN- early in
infection on the timing and quality of the adaptive immune re-
sponse to PRRSV. Because there is little IFN- produced during
PRRSV infection and IFN- plays a role in the development of the
adaptive immune response as well as the innate immune response,
we hypothesized that this might be one reason that there is an
inadequate adaptive response to the virus. To test this hypothesis,
we followed aspects of the adaptive immune response, both anti-
body- and cell-mediated immunity, in pigs simultaneously ad-
ministered Ad5–pIFN- and PRRSV and compared them to the
response in pigs exposed only to PRRSV.
MATERIALS AND METHODS
Experimental design and viruses. A recombinant, replication-defective
human adenovirus type 5 was used to deliver porcine IFN- (Ad5–
pIFN-) as previously described (6). Twenty-eight, 6-week-old pigs were
divided into 3 groups of 9 to 10 pigs each and given the following treat-
ments: group 1, Ad5–pIFN- but no PRRSV; group 2, Ad5–pIFN- and
PRRSV; and group 3, Ad5 not expressing pIFN- (Ad5-null) and PRRSV.
On day 0 of the experiment, pigs were given 5  109 focus-forming units
(FFU) of the respective Ad5 constructs intramuscularly in the neck, and
pigs in groups 2 and 3 were challenged with 104 median cell culture infec-
tious doses (CCID50s) of the SDSU73 strain of PRRSV intranasally, while
the pigs in group 1 were mock challenged with medium from noninfected
cell cultures. Blood samples were collected on days 0 to 7, 9, 11, 13 or 14,
and 16 and then weekly from days 21 through 56. Four to five pigs from
each group were euthanized 14 days after challenge with PRRSV, and the
other five pigs from each group were euthanized 56 days after challenge
with PRRSV.
IFN- ELISA. IFN- levels in the sera were determined by enzyme-
linked immunosorbent assay (ELISA) using monoclonal antibody (MAb)
F17 and MAb K9 conjugated to horseradish peroxidase (PBL Interferon
Source) as previously described (9, 14). Briefly, 96-well Immulon-2 plates
were coated with 3 g F17 MAb. Samples set up in duplicate were added to
each well, and plates were incubated and washed prior to the addition of
peroxidase-conjugated K9 (1:10,000). Plates were again washed, tetram-
ethylbenzidine substrate solution was added to each well, and the optical
density was measured at 450 nm by an ELISA plate reader. Quantified
recombinant porcine IFN- was used as a standard, and IFN- concen-
trations were calculated on the basis of a standard curve.
PRRSV isolation and detection. Viremia was measured by both virus
isolation and real-time reverse transcription-PCR (RT-PCR). Virus isola-
tion was performed by adding 100 l of serum to 1 well of a 24-well plate
containing a monolayer of MARC-145 cells in 1 ml of cell culture me-
dium. After 2 h, medium in the well was removed and replaced with fresh
medium. Each well was examined for cytopathic effect (CPE) and assessed
as positive or negative after 1 week of culture. A real-time RT-PCR assay
for PRRSV was used to quantify viral RNA (vRNA) in the serum of pigs as
previously described (18). Briefly, viral RNA was isolated from 140 l of
each serum sample using a commercial kit (viral RNA isolation kit;
Qiagen), and the viral RNA was eluted into 60 l. Eight microliters of the
eluted RNA sample was then used with a one-step RT-PCR kit (Qiagen)
according to the manufacturer’s recommendations. Viral RNA was ex-
tracted from a stock of SDSU73 virus, and an 8-point standard curve (1:10
dilutions) was generated and used in the same one-step RT-PCR as RNA
extracted from each sample. Results are expressed as the amount of vRNA
relative to the standard curve.
PRRSV antibody detection. Seroconversion to PRRSV was deter-
mined by an ELISA kit. ELISA sample-to-positive (S/P) ratios were gen-
erated on collected serum samples by performing the HerdCheck PRRS
ELISA 2XR (IDEXX Laboratories) according to the manufacturer’s in-
structions.
Virus-neutralizing antibody responses were determined using a fluo-
rescent focus neutralization (FFN) assay as previously described (39).
Briefly, 2-fold dilutions of heat-inactivated serum samples were incubated
with the homologous virus isolate (SDSU73) prior to infection of MARC-
145 cells. Endpoints were reported as the highest serum dilution showing
a 90% or greater reduction in the number of fluorescent foci.
ELISpot assays. To assess antigen-specific IFN- responses, approxi-
mately 8 ml of blood was collected at the time points indicated into BD
Vacutainer CPT tubes with sodium citrate, and the peripheral blood
mononuclear cell (PBMC) fraction was collected according to the manu-
facturer’s recommendations. PBMCs were washed once with RPMI 1640
(Invitrogen), passed through a 40-m-pore-size screen filter, washed a
second time, and enumerated. An enzyme-linked immunosorbent spot
(ELISpot) assay for IFN--secreting cells was performed as previously
described with slight modifications (42). Briefly, 96-well membrane plates
(MAIPS4510) were prewetted with 35% ethanol, washed, and coated
overnight at 4°C with 6 g/ml anti-pIFN- (P2G10; BD Biosciences). The
next day, the plate was washed and blocked with complete RPMI (RPMI
1640, 10% fetal bovine serum, 2 mM L-glutamine, 1% antibiotic/antimy-
cotic [Invitrogen], and gentamicin) for 2 h at 37°C. The blocking medium
was removed, and 5  105 PBMCs were plated per well. Appropriate wells
were treated with live homologous PRRSV at a multiplicity of infection of
1 (SDSU73), control MARC medium, or phytohemagglutinin (PHA)
added to a final concentration of 10 g/ml (each treatment in triplicate),
and the plates were incubated for 18 h at 37°C in 5% CO2. After 18 h,
plates were washed and incubated with anti-IFN- detection antibody
(0.5 g/ml; P2C11; BD Biosciences) for 2 h at 37°C. Plates were washed
and developed using an ELISpot blue color module (R&D Systems) ac-
cording to the manufacturer’s recommendations. Plates were scanned,
and spots were enumerated using a CTL-ImmunoSpot S5 UV analyzer
and ImmunoSpot software. The number of PBMC samples analyzed for
each treatment group ranged from 4 to 5.
Multiplex cytokine assay. Approximately 5 ml of bronchoalveolar
lavage fluid (BALF) was centrifuged at 300  g for 10 min at 4°C to pellet
cellular debris. The cell-free BALF was tested for levels of IL-1, IL-8, IL-6,
TNF-, IL-2, IL-4, IL-12p70, IFN-, and IL-10 by a SearchLight multiplex
ELISA performed according to the manufacturer’s recommendations
(Aushon Biosystems, Billerica, MA). The average of duplicate wells for
each sample was used for statistical analysis.
Statistical analysis. Viremia, ELISpot assay, and antibody response
data were analyzed using a mixed linear model for repeated measures
(SAS, version 9.1, for Windows; SAS Institute Inc.). Linear combinations
of the least-squares sample estimates were used in a priori contrasts, after
testing for either a significant (P  0.05) treatment effect or an interaction
effect between time point and experimental treatment. Comparisons be-
tween treatment groups were made at each time point using a 5% level of
significance (P  0.05) to assess statistical differences. Cytokine data were
compared using a one-way analysis of variance with a Tukey’s posttest at
a significance level of P of 0.05.
RESULTS
Serum IFN- levels. An IFN- ELISA was run on serum samples
to determine the magnitude and duration of IFN- production in
response to administration of the Ad5–pIFN- and/or PRRSV
infection. No IFN- was detected in the serum of any of the pigs
on day 0. Pigs in both groups given the Ad5–pIFN- had similar
levels of IFN- in their serum, which were high on day 1 but
declined rapidly after that (Fig. 1). IFN- levels in the pigs given
Ad5-null and challenged with PRRSV peaked on day 2 but were
much lower than peak levels induced by the Ad5–pIFN- (Fig. 1).
Viremia and viral RNA loads. Both virus isolation and quan-
titative PCR were used to determine the extent of viremia as a
measure of the degree of virus replication in the pigs. PRRSV was
not isolated from the serum of any mock-infected pig or from any
sample from PRRSV-infected pigs taken on day 0. PRRSV was
detected by virus isolation in the serum of pigs receiving the Ad5-
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null earlier than in the serum of pigs receiving the Ad5–pIFN-,
indicating that the presence of IFN- delayed viremia (Fig. 2).
Virus was isolated from the sera of pigs in the Ad5-null/PRRSV
group as early as day 1 postinfection, whereas the earliest isolation
of virus from the sera of pigs in the group receiving Ad5–pIFN-
was day 3. Differences in virus isolation between the two experi-
mental groups were pronounced at days 2 and 3 postinfection,
when the isolation of PRRSV from serum samples was 60% in
the Ad5-null/PRRSV group. In addition, the level of PRRSV in the
serum detected by quantitative PCR on days 5 through 9 was also
significantly lower for pigs that received the Ad5–pIFN- (Fig. 2),
even though the incidence of detecting PRRSV in serum during
this time was similar between the 2 groups. At later time points
postinfection, there was no significant difference in the amount of
vRNA detected between the 2 challenged groups. On day 14
postinfection, PRRSV was isolated from the lung lavage fluid of all
PRRSV-challenged pigs, regardless of Ad5–pIFN- treatment
(data not shown).
Antibody response. An ELISA was run on serum samples to
determine when pigs seroconverted and the total antibody re-
sponse to PRRSV. On the basis of the ELISA results, pigs given
Ad5–pIFN- and then challenged with PRRSV seroconverted to
PRRSV later than pigs challenged with PRRSV given Ad5-null
(Fig. 3A). Using the recommended cutoff value of an S/P ratio of
0.400, the pigs in the group given Ad5-null, on average, serocon-
verted to PRRSV by day 7 postinfection, and the S/P ratio on this
day was significantly higher for these pigs than for the pigs in the
group given Ad5–pIFN-, none of which had seroconverted by
day 7. After day 7, there was no significant difference in the anti-
body levels between the groups challenged with PRRSV. None of
the pigs in the noninfected group seroconverted to PRRSV. The
IDEXX ELISA is useful for measuring seroconversion, but it does
not specifically measure neutralizing antibody levels. To better
evaluate neutralizing antibody responses, an FFN assay was per-
formed. While there was a trend toward increased neutralizing
antibody levels and a more rapid appearance of neutralizing anti-
body (day 21) in the group given Ad5–pIFN-, the differences
were not statistically significant (Fig. 3b).
Antigen-specific IFN- response. To better understand the
effects of Ad5–pIFN- administration on the cellular immune
response to PRRSV, an IFN- ELISpot assay was used to enumer-
ate the number of antigen-specific IFN--secreting cells (ISCs)
circulating in the peripheral blood. It was not until 28 days follow-
ing challenge that PRRSV-specific ISCs were detected, regardless
FIG 1 Serum levels of IFN- after inoculation with Ad5–IFN- or Ad5-null
and PRRSV or mock challenge with medium from noninfected cell culture.
Data are expressed as the mean  SEM of 9 pigs in each of the Ad5–IFN-/
PRRSV and Ad5–IFN-/mock groups and 10 pigs in the Ad5-null/PRRSV
group through day 9; subsequently, the mean is based on 4 to 5 pigs per group.
FIG 2 Levels of PRRSV vRNA in serum detected by real-time PCR after inoculation with Ad5–IFN- or Ad5-null and PRRSV or mock challenge with medium
from noninfected cell culture. The data are expressed as the mean  SEM of 9 pigs in the Ad5–IFN-/PRRSV group and 10 pigs in the Ad5-null/PRRSV group
through day 9 postinfection; subsequently, the mean is based on 4 to 5 pigs per group. The values above each data point on the graph refer to the number of
positive samples based on virus isolation per total number of samples for the Ad5-null/PRRSV group, and the values below each data point refer to the same data
for the Ad5–IFN-/PRRSV group. No PRRSV vRNA was detected, nor was PRRSV isolated from any of the samples collected from pigs in the Ad5–IFN-/mock
group. *, statistically significant differences at P  0.05.
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of the administration of Ad5–pIFN-. However, on day 28 there
were significantly more ISCs in pigs that received the Ad5–
pIFN-. Overall, higher numbers of ISCs were detected in the
peripheral blood cells of pigs given Ad5–pIFN- from days 28
through 43, and these numbers were significantly higher on days
28 and 43 (Fig. 4).
Cytokines in BALF. A subset of pigs in each group was eutha-
nized on day 14 postinfection to evaluate local host responses in
the lung. In general, a trend toward increased levels of IL-1, IL-8,
TNF-, IL-10, and IFN- was detected in the BALF of PRRSV-
infected pigs (regardless of Ad5–pIFN- administration) than
that of noninfected pigs (Fig. 5). However, PRRSV-infected pigs
that were given Ad5–pIFN- had lower levels of IL-6, IL-8,
TNF-, IL-10, and IFN- than PRRSV-infected pigs given Ad5-
null, though the difference was statistically significant only for
TNF-. The remaining cytokine analyzed, IL-1, was expressed at
very similar levels in both groups of PRRSV-infected pigs (Fig. 5).
There were no significant differences in the levels of IL-12p70,
IL-2, or IL-4 among the 3 groups (data not shown).
DISCUSSION
The pleiotropic cytokine IFN- is involved in many aspects of the
host immune response at both the innate and the adaptive levels.
It can exert potent antiviral effects by initiating the production of
various antiviral mediators that hinder viral replication and pack-
aging. IFN- can also act on antigen-presenting cells to enhance
their ability to activate lymphocytes through production of cyto-
kines and expression of antigen-presentation molecules. In addi-
tion, IFN- can act directly on T cells to drive maturation from a
naïve T cell to an effector cell (12). IFN- is typically produced in
response to a viral infection, but it is well accepted that PRRSV
does not induce a strong IFN- response, which may secondarily
affect development of the adaptive immune response. It has been
hypothesized that administration of IFN-, as a recombinant pro-
tein or through in vivo expression of the cloned gene, may enhance
the host response to PRRSV, aiding in clearance and increased
adaptive immunity.
A previous report by our group showed that prophylactic ad-
FIG 3 Antibody response to PRRSV after inoculation with Ad5–IFN- or Ad5-null and PRRSV or mock challenge with medium from noninfected cell culture.
Serum antibody response to PRRSV was evaluated by determination of the S/P ratio using IDEXX ELISA (A) or FFN assay (B). (A) Data are expressed as the
mean  SEM of 9 pigs in each of the Ad5–IFN-/PRRSV and Ad5–IFN-/mock groups and 10 pigs in the Ad5-null/PRRSV group until 9 days postinfection;
subsequently, the mean is based on 4 to 5 pigs per group. (B) Data are expressed as the mean  SEM for 5 pigs in both the Ad5–IFN-/PRRSV and
Ad5-null/PRRSV groups. FFN titers in the Ad5–IFN-/mock group were negative at every time point tested. *, statistically significant differences at P  0.05.
FIG 4 Number of PRRSV-specific IFN--secreting cells (SC) after inoculation with Ad5–IFN- or Ad5-null and PRRSV or mock challenge with noninfected cell
culture and medium. Data are expressed as the mean  SEM for 5 pigs in all the groups. *, statistically significant differences at P  0.05.
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ministration of Ad5–pIFN- to pigs resulted in increased levels of
circulating IFN- for approximately 2 days and this was able to
attenuate PRRSV disease severity when given 1 day prior to
PRRSV exposure (6). However, effects on development of the an-
tigen-specific immune response were not considered in that first
study. The study reported here was extended to 56 days postinfec-
tion in order to monitor PRRSV-specific responses. The timing of
Ad5–pIFN- administration was also altered to assess the effec-
tiveness of the construct as a potential adjuvant or metaphylactic
when given coincident with potential exposure to PRRSV, for ex-
ample, when pigs are moved to a new facility and/or mixed with
pigs potentially infected with PRRSV.
Similar to the results reported in the prior study, in the current
study there was an initial delay in the detection of vRNA in the sera
of pigs given the Ad5–pIFN- construct, concurrent with the time
at which serum IFN- levels were highest (6). Whereas by day 3
postinfection most of the pigs in the previous experiment were
viremic whether or not they received IFN-, the majority of pigs
receiving IFN- in this experiment did not become viremic until
day 4. This is likely due to the timing of Ad5–pIFN- administra-
tion. Specifically, Ad5–pIFN- was given 1 day prior to infection
in the previous experiment, as opposed to the same day as PRRSV
challenge in this experiment. Unlike the previous experiment,
however, exposure to IFN- did result in a significant decrease in
the amount of PRRS vRNA between days 5 and 9 postinfection,
although it did not affect the incidence of viremia during the same
time period. Thus, while administration of the Ad5–pIFN- con-
struct did not prevent the occurrence of viremia, it did signifi-
cantly decrease the amount of vRNA circulating in the blood. Our
data demonstrate that a single dose of Ad5–pIFN-, when admin-
istered on the same day as PRRSV challenge, can control early viral
replication and viremia and lower peak virus levels found in the
serum.
In a prior report, we demonstrated that the onset of viremia in
pigs given a low dose of PRRSV is delayed compared to the onset
of viremia in pigs receiving a higher dose, although the amount of
vRNA subsequently detected in the sera is unaffected (19). This
mirrors the delay in viremia observed in our previous experiment
giving Ad5–pIFN- 1 day prior to challenge with PRRSV (6). In
the current experiment, not only was there a delay in the onset of
viremia but also there were subsequently decreased viral loads in
the peripheral blood as well. Thus, it is unlikely that Ad5–pIFN-
alone controlled viral loads in the current experiment because we
would have expected vRNA levels to be the same between groups
once IFN- levels returned to normal in the Ad5–pIFN- group,
which was by day 3. Because vRNA levels remained relatively low
in the Ad5–pIFN- group, we speculate that additional control/
activation mechanisms were initiated with Ad5–pIFN- adminis-
tration. Further work is warranted to understand the innate anti-
viral response and to define mechanisms of controlling viral load
at early time points following Ad5–pIFN- administration.
By evaluating the adaptive immune responses, our data show
that administration of Ad5–pIFN- on the day of PRRSV chal-
lenge can significantly alter the ensuing T cell response but has a
less pronounced effect on antibody responses. Seroconversion, as
measured by IDEXX ELISA, was delayed in pigs given the Ad5–
pIFN- construct compared to pigs given the Ad5-null construct,
presumably due to the delay in viral replication and/or antigen
load. However, this was detected only on day 7 postinfection, and
there was no significant difference between the groups by day 9
postinfection. Neutralizing antibody titers also did not differ sig-
nificantly between the two groups, though a trend toward in-
creased neutralization titers on days 21 and 28 in the Ad5–pIFN-
group was appreciated. There was, however, an increase in the
number of antigen-specific ISCs in the periphery of pigs given the
Ad5–pIFN- construct. These results are similar to those reported
by Meier et al., who coadministered IFN- with a modified live
PRRSV vaccine and found an increase in PRRSV antigen-specific
ISCs but no effect on the production of antivirus antibodies (23).
IFN- is known to have effects on antigen-presenting cells but has
also been shown to act directly on naïve T cells to drive differen-
tiation into effector T cells (reviewed in reference 12). The contri-
bution of ISCs to PRRSV clearance has not been clearly defined,
and it is difficult to assess their contribution in the current study,
as viral clearance or control in the sera was apparent on day 21
postinfection but PRRSV ISCs were not detectable in the periph-
eral blood until day 28 postinfection. Neutralizing antibody titers
were detectable in a few pigs in the Ad5–pIFN- group on day 21,
although viral loads were decreasing by this time point. There are
several reports suggesting that neutralizing antibodies do not cor-
relate with decreased viremia (29, 41), while some papers suggest
that titers must be extremely high to provide protection (17, 28).
Since we did not attempt rechallenge, we do not know whether the
changes in the immune response to PRRSV seen in the presence of
IFN- would have been more efficacious in preventing clinical
signs or inducing viral clearance in pigs reexposed to homologous
or heterologous PRRSV. Further studies would be needed to ex-
plore this possibility.
FIG 5 Cytokine levels in BALF 14 days after inoculation with Ad5–IFN- or Ad5-null and PRRSV or mock challenge with medium from noninfected cell culture.
Data are expressed as the mean  SEM of 4 pigs in the Ad5–IFN-/PRRSV and Ad5–IFN-/mock groups and 5 pigs in the Ad5-null/PRRSV group.
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The presence of IFN- at PRRSV challenge altered the cytokine
profile observed in the lung lavage fluid at day 14 postinfection.
Although IL-1 levels were unchanged, there was a trend toward
lower levels of IL-10 and IFN-, as well as the proinflammatory
cytokines IL-6, IL-8, and TNF-. Whether the delay in viral rep-
lication, lowered viral titers, and/or activation mechanisms initi-
ated by increased levels of IFN- influenced these differences is
unknown, and these results do reflect a snapshot in time. How-
ever, PRRSV induction of IL-10 has been postulated to be at least
partially responsible for some of its immunosuppressive effects (8,
10, 33, 34). Thus, it is tempting to speculate that the decrease in
IL-10 may be associated with the increase in PRRSV-specific ISCs
detected in pigs administered the Ad5–pIFN-.
Overall, we have demonstrated that the administration of
pIFN- at the time of challenge can reduce the severity of PRRSV
disease and decrease vRNA loads. However, until dependable cor-
relates of protection for PRRSV are identified, it will continue to
be difficult to assess the impact of different therapeutics and/or
adjuvants on specific immune parameters. At this time, without
rechallenge, we are unable to say for sure whether the increased
antigen-specific IFN--secreting cells would actually contribute
to protection. While it is necessary to continue to identify factors
that control viremia, such as IFN-, it is also necessary to under-
stand how PRRSV subverts the host immune response to its ben-
efit and identify the mechanisms that the host uses to clear the
virus.
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